A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial*

the IXORA-R Study Group

doi:10.1111/bjd.19509

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial*

the IXORA-R Study Group

Inernational Relations Division

Research output: Contribution to journal › Article › peer-review

74 Citations (Scopus)

Original language	English
Pages (from-to)	1047-1058
Number of pages	12
Journal	British Journal of Dermatology
Volume	184
Issue number	6
DOIs	https://doi.org/10.1111/bjd.19509
Publication status	Published - Jun 2021

ASJC Scopus Subject Areas

Dermatology

Access to Document

10.1111/bjd.19509

Cite this

@article{98591fe6228041ba91af4b427c94ac26,

title = "A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial*",

author = "{the IXORA-R Study Group} and A. Blauvelt and C. Leonardi and B. Elewski and Crowley, {J. J.} and Guenther, {L. C.} and M. Gooderham and Langley, {R. G.} and R. Vender and A. Pinter and Griffiths, {C. E.M.} and Y. Tada and H. Elmaraghy and Lima, {R. G.} and G. Gallo and L. Renda and R. Burge and Park, {S. Y.} and B. Zhu and K. Papp",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists",

year = "2021",

month = jun,

doi = "10.1111/bjd.19509",

language = "English",

volume = "184",

pages = "1047--1058",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis

T2 - 24-week efficacy and safety results from a randomized, double-blinded trial*

AU - the IXORA-R Study Group

AU - Blauvelt, A.

AU - Leonardi, C.

AU - Elewski, B.

AU - Crowley, J. J.

AU - Guenther, L. C.

AU - Gooderham, M.

AU - Langley, R. G.

AU - Vender, R.

AU - Pinter, A.

AU - Griffiths, C. E.M.

AU - Tada, Y.

AU - Elmaraghy, H.

AU - Lima, R. G.

AU - Gallo, G.

AU - Renda, L.

AU - Burge, R.

AU - Park, S. Y.

AU - Zhu, B.

AU - Papp, K.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85093966402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85093966402&partnerID=8YFLogxK

U2 - 10.1111/bjd.19509

DO - 10.1111/bjd.19509

M3 - Article

C2 - 32880909

AN - SCOPUS:85093966402

SN - 0007-0963

VL - 184

SP - 1047

EP - 1058

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 6

ER -

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial*

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this